Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/149542/1/apt15263_am.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/149542/2/apt15263.pd
Introduction: Immunotherapy with anti CTLA-4 (Ipilimumab) or anti PD-1 (Pembrolizumab, Nivolumab) an...
INTRODUCTION: Systemic corticosteroids are the mainstay of treatment for immune checkpoint inhibitor...
To investigate management of patients who develop ipilimumab-mediated enterocolitis, including assoc...
Colitis can be a life-threatening immune-related adverse event (irAE) for patients with metastatic m...
Background Immune-related colitis is a common, often serious complication of immune checkpoint inhib...
Background/aims: Among the severe immune-related adverse events (irAEs) that occur with immune check...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/151368/1/apt15448_am.pdfhttps://deepbl...
Background: Immune checkpoint inhibitors are successfully introduced as anticancer treatment. Howeve...
Abstract Background Immune checkpoint inhibitors (ICPI) are efficacious treatments for advanced mali...
BackgroundImmune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse event...
As the use of immune checkpoint inhibitors for several different malignancies becomes more mainstrea...
Immune checkpoint inhibitors (ICPIs) are novel therapeutic agents targeting a variety of cancers by ...
Background: Immune checkpoint inhibitors have revolutionised cancer treatment, but at the cost of of...
PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with c...
BACKGROUND & AIMS: Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated antig...
Introduction: Immunotherapy with anti CTLA-4 (Ipilimumab) or anti PD-1 (Pembrolizumab, Nivolumab) an...
INTRODUCTION: Systemic corticosteroids are the mainstay of treatment for immune checkpoint inhibitor...
To investigate management of patients who develop ipilimumab-mediated enterocolitis, including assoc...
Colitis can be a life-threatening immune-related adverse event (irAE) for patients with metastatic m...
Background Immune-related colitis is a common, often serious complication of immune checkpoint inhib...
Background/aims: Among the severe immune-related adverse events (irAEs) that occur with immune check...
Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/151368/1/apt15448_am.pdfhttps://deepbl...
Background: Immune checkpoint inhibitors are successfully introduced as anticancer treatment. Howeve...
Abstract Background Immune checkpoint inhibitors (ICPI) are efficacious treatments for advanced mali...
BackgroundImmune checkpoint inhibitors (ICI) improve survival but cause immune-related adverse event...
As the use of immune checkpoint inhibitors for several different malignancies becomes more mainstrea...
Immune checkpoint inhibitors (ICPIs) are novel therapeutic agents targeting a variety of cancers by ...
Background: Immune checkpoint inhibitors have revolutionised cancer treatment, but at the cost of of...
PURPOSE The risk of immune checkpoint inhibitor therapy–related GI adverse events in patients with c...
BACKGROUND & AIMS: Ipilimumab, a monoclonal antibody against cytotoxic T-lymphocyte-associated antig...
Introduction: Immunotherapy with anti CTLA-4 (Ipilimumab) or anti PD-1 (Pembrolizumab, Nivolumab) an...
INTRODUCTION: Systemic corticosteroids are the mainstay of treatment for immune checkpoint inhibitor...
To investigate management of patients who develop ipilimumab-mediated enterocolitis, including assoc...